Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the firm, Marketbeat reports. Rapport Therapeutics Stock PerformanceNASDAQ RAPP opened at $46.35 on Friday. Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last announced its earnings results on Wednesday, August 5th. Rapport Therapeutics Company Profile(Get Free Report)Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. Further ReadingReceive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.